scholarly journals Effect of Low-molecular Pectin and Metformin on Paclitaxel Toxicity in Rats with Walker Carcinosarcoma

2021 ◽  
Vol 7 (11) ◽  
pp. 142-146
Keyword(s):  
Tumor Regression ◽  
Live Weight ◽  
Antagonistic Effect ◽  
Inhibition Of Tumor Growth ◽  
Low Toxicity ◽  
Regulatory Effects ◽  
Reduction Effect ◽  
High Doses ◽  
High Bioavailability ◽  
Complete Tumor

Recently, researchers have been particularly interested in the use of herbal agents in combination therapy of tumors with a spectrum of regulatory effects, low toxicity, and high bioavailability, as well as drugs that indirectly affect the growth and metastasis of tumor cells. The article presents the results of experiments on the study of the combined effect of metformin, low molecular weight pectin and cytostatic agent — paclitaxel on the transplantable tumor — Walker’s carcinosarcoma 256, in order to reduce the toxic effect of the chemotherapy drug. With the combined administration of pectin and paclitaxel (10 mg/kg), metformin and paclitaxel (10 mg/kg), inhibition of tumor growth was observed. On the 25th day, the death of 50% of the animals was observed in the first group, and in the remaining 50%, complete tumor regression was observed. With a single administration of paclitaxel at a single dose of 10 mg / kg of live weight, 62.5% of the animals died in the first 4 days. The combination of drugs (pectin + metformin + paclitaxel) at various single doses of paclitaxel (10, 20, and 25 mg/kg) had an antagonistic effect, showing worse results than the use of each drug with a cytostatic alone (death of animals in the period from 1 to 6 days). Thus, the experimental results demonstrated a clear toxicity reduction effect at high doses of paclitaxel in combination with pectin or metformin.

Radioimmunotherapy of Xenografts of Human Pancreatic Carcinomas - Intravenous and Intratumoral Application of 131l-Labelled Monoclonal Antibodies

1986 ◽  
Vol 25 (06) ◽  
pp. 235-238 ◽  
Author(s):  
S. Lander ◽  
M. Bahlo ◽  
R. Montz ◽  
R. Klapdor
Keyword(s):  
Irradiation Dose ◽  
Tumor Regression ◽  
Whole Body ◽  
Inhibit Tumor Growth ◽  
Local Irradiation ◽  
Clinical Value ◽  
Direct Radiation ◽  
Intravenous Injections ◽  
Induce Tumor Regression ◽  
High Doses

The effects of radioimmunotherapy were tested in xenografts of 2 different human pancreatic carcinomas comparing the intravenous and intratumoral application. On principle, intravenous injections of high doses of 131l-anti- Ca 19-9 or -BW 494/32 may inhibit tumor growth. In view of the low direct radiation dose (360-2100 rad), however, other factors than direct toxic effects have to be discussed, e. g. systemic effects due to the high whole-body irradiation. Intratumoral application, however, may induce tumor regression or growth inhibition due to the high local irradiation dose. Consequently, this treatment modality might be of clinical value at least in some patients.

scholarly journals In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1051
Author(s):  
Christopher Montemagno ◽  
Florian Raes ◽  
Mitra Ahmadi ◽  
Sandrine Bacot ◽  
Marlène Debiossat ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Tumor Volume ◽  
Tumor Regression ◽  
Efficacy Evaluation ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Target Organs ◽  
G Protein Coupled ◽  
Complete Tumor

NeoB is a radiotracer targeting the gastrin-releasing peptide receptor (GRPR), a G-protein–coupled receptor expressed in various cancers. The aim of the present study was to evaluate the biodistribution and efficacy of this new therapeutic agent in Gastrointestinal Stromal Tumors (GIST). Eighty-two SCID mice bearing GIST-882 tumors were employed. [177Lu]Lu-NeoB biodistribution was evaluated up to seven days by organ sampling (200 pmol/0.8 MBq, i.v.). For efficacy evaluation, mice received either saline, 400 pmol or 800 pmol of [177Lu]Lu-NeoB (37MBq, 1/w, 3 w, i.v.). SPECT/CT imaging was performed at 24 h, and tumor volume was determined up to 100 days. Elevated and specific [177Lu]Lu-NeoB uptake was found in the GIST tumor, as demonstrated by in vivo competition (19.1 ± 3.9 %ID/g vs. 0.3 ± 0.1 %ID/g at 4h). [177Lu]Lu-NeoB tumor retention (half-life of 40.2 h) resulted in elevated tumor-to-background ratios. Tumor volumes were significantly reduced in both treated groups (p < 0.01), even leading to complete tumor regression at the 400 pmol dose. [177Lu]Lu-NeoB exhibited excellent pharmacokinetics with elevated and prolonged tumor uptake and low uptake in non-target organs such as pancreas. The potential of this new theragnostic agent in different indications, including GIST, is under evaluation in the FIH [177Lu]Lu-NeoB clinical trial.

scholarly journals Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor

2010 ◽  
Vol 53 (5) ◽  
pp. 1101-1108 ◽  
Author(s):  
Fernando Guimarães ◽  
Alessandra Soares Schanoski ◽  
Tereza Cristina Samico Cavalcanti ◽  
Priscila Bianchi Juliano ◽  
Ana Neuza Viera-Matos ◽  
...  
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Wistar Rats ◽  
Tumor Regression ◽  
Growth Characteristics ◽  
Tumor Growth Rate ◽  
Continuous Growth ◽  
Tumor Bearing ◽  
Walker 256 ◽  
Complete Tumor

The present study aimed at characterizing the subcutaneous development of the Walker 256 (W256) AR tumor, a regressive variant of the rat W256 A tumor. Wistar rats were injected subcutaneously with 4x10(6) W256 A or W256 AR tumor cells. The development of tumors was evaluated daily by percutaneous measurements. None of the W256 A tumors (n=20) regressed, but 62% of the W256 AR tumor-bearing rats (n=21) underwent complete tumor regression within 35 days. Continuous growth of AR tumors was characterized by an increase of the tumor growth rate from day 12, which reached values above 1.0 g/day, and were significantly higher (p<0.05) than those of the regressive AR tumors. Immunosuppression by irradiation before subcutaneous injection of AR cells completely abrogated tumor regression and was associated with severe metastatic dissemination. Daily evaluation of the tumor growth rate enabled the discrimination, in advance, between continuously growing tumors and those that regressed later on.

scholarly journals Carbon ion radiotherapy with complete tumor regression for primary malignant melanoma of female urethra orifice: a case report

2022 ◽  
Vol 50 (1) ◽  
pp. 030006052110727
Author(s):  
Xiaojun Li ◽  
Yihe Zhang ◽  
Yanshan Zhang ◽  
Yancheng Ye ◽  
Ying Qi ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Tumor Regression ◽  
Treatment Protocol ◽  
Carbon Ion Radiotherapy ◽  
Primary Malignant Melanoma ◽  
Radiation Dermatitis ◽  
Survival Duration ◽  
Female Urethra ◽  
Carbon Ion ◽  
Complete Tumor

Primary malignant melanoma of the female urethra (PMMFU) is extremely rare, accounting for 0.2% of all melanomas, and fewer than 200 cases have been reported worldwide. Because of the small number of clinical cases and unclear biological characteristics, there is no uniform and standard treatment protocol. We herein describe the treatment of PMMFU using carbon ion radiotherapy. The radiotherapy was delivered at 60.8 Gy (RBE) in 16 fractions, once daily, five times per week. The patient achieved complete tumor disappearance within 1 year after carbon ion radiotherapy and remained disease-free thereafter. She developed acute grade 1 radiation dermatitis and urethritis, which resolved quickly; no other toxic effects were observed. At the time of this writing, her survival duration was 33 months. This case demonstrates that carbon ion radiotherapy may be a good option for primary genitourinary mucosal malignancies.

scholarly journals Persistent Retinal Detachment in Retinoblastoma: The Challenges

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Sophia El Hamichi ◽  
Dhariana Acon ◽  
Veronica Kon Graversen ◽  
Aaron S. Gold ◽  
Audina M. Berrocal ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Tumor Regression ◽  
Treatment Options ◽  
Local Treatment ◽  
Visual Outcome ◽  
Poor Visual Outcome ◽  
Age Of Diagnosis ◽  
The Mean ◽  
Ophthalmological Assessment ◽  
Complete Tumor

Introduction. Retinoblastoma (RB) is the most common eye tumor in children. There have been significant improvements in treatment options targeting killing the tumor while also conserving the eye and attempting to conserve functional vision. Retinal detachment (RD) is not an uncommon event and compromises the vision and sometimes RB treatment. Materials and Methods. Retrospective review of 62 patients over a period of 8 years between 2012 and 2019 with eyes treated for RB and having persistent RD that did not resolve after complete tumor regression. Results. Forty-two patients of these 62 cases developed RD (67%). The RD resolved in 35 patients (83% of RD), and 7 patients (16% of RD) developed a persistent RD. In all the persistent RD groups (7 patients/11 eyes), RB and RD were present simultaneously in the first ophthalmological assessment. Sex ratio was 2 females/5 males. The mean age of diagnosis was 11 months. All eyes had advanced RB stages. Eight eyes had local treatment with transpupillary laser, 6 eyes received IAC, and 3 patients received systemic chemotherapy. In 9 eyes, the RD had both exudative and tractional components. Only one eye had a pure tractional RD due to persistent fetal vasculature, and one eye had rhegmatogenous RD component with presence of a tear in addition to exudation. None of the eyes received RD surgical repair. Conclusion. Persistent RD occurs in eyes with advanced RB stages with complex RD with more than one component. The dilemma is performing a vitrectomy in eyes with cancer and poor visual outcome.

scholarly journals Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein

Blood ◽  
1994 ◽  
Vol 83 (4) ◽  
pp. 899-906 ◽  
Author(s):  
WM Vuist ◽  
R Levy ◽  
DG Maloney
Keyword(s):  
Signal Transduction ◽  
Tumor Cells ◽  
Tyrosine Phosphorylation ◽  
Tumor Regression ◽  
Cellular Protein ◽  
Protein Tyrosine Phosphorylation ◽  
Custom Made ◽  
Tumor Expression ◽  
Complete Tumor

Abstract Custom-made monoclonal anti-idiotype antibodies (anti-Id MoAbs) have been tested as a treatment modality in 34 non-Hodgkin's lymphoma (NHL) patients. Partial or complete tumor remissions have been induced with this treatment in 68% of these patients. One mechanism by which anti- idiotype antibodies may have induced these tumor responses is via a direct antiproliferative effect on the tumor cells, resulting in apoptosis. Primary NHL cells do not proliferate well enough in vitro to test this hypothesis directly. Therefore, we studied the effect of anti-idiotype antibodies on signal transduction through the surface Ig receptor as measured by the induction of cellular protein tyrosine phosphorylation. To assess whether bcl-2 protein could protect lymphoma cells from death induced by anti-Id MoAb, we also measured the level of bcl-2 protein in the same tumor cells. We found a strong correlation between the ability of an anti-Id MoAb to induce an increase in tyrosine phosphorylation in vitro and its ability to induce a tumor regression in the patient. By contrast, the level of bcl-2 expressed by the tumor cells was not correlated with clinical response to anti-Id MoAb treatment.

Sign in / Sign up

Export Citation Format

Share Document